(7S,9R)-7-[(2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,11-dihydroxy-9-(2-hydroxyacetyl)-4-methoxy-9-methyl-8,10-dihydro-7H-tetracene-5,12-dione

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: (7S,9R)-7-[(2S,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,11-dihydroxy-9-(2-hydroxyacetyl)-4-methoxy-9-methyl-8,10-dihydro-7H-tetracene-5,12-dione
• 化学式: C₂₈H₃₁NO₁₀
• 分子量: 541.5
• InChiKey: MMUMKCAZQQPSJR-HMBFAIOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  39
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  186
• 氢给体数：
  5
• 氢受体数：
  11

文献信息

• Methods and compositions for prediction of therapeutic efficacy of cancer treatments and cancer prognosis upon antibody treatment
  申请人：STRATIFYER Molecular Pathology GmbH

  公开号：EP2910645A1

  公开（公告）日：2015-08-26

  The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.

  本发明一般涉及预测癌症治疗疗效和癌症预后的方法和组合物。本发明公开了在某些癌症治疗中分别与有利和不利结果相关的标记物，这些标记物可作为癌症的预后标记物。本发明公开了涉及这些标记物的方法，用于预测癌症治疗效果和癌症患者的临床预后。
• Combination therapy involving antibodies against Claudin 18.2 for treatment of cancer
  申请人：Ganymed Pharmaceuticals AG

  公开号：US10022444B2

  公开（公告）日：2018-07-17

  The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

  本发明提供了一种联合疗法，可有效治疗和/或预防与表达CLDN18.2的细胞有关的疾病，包括胃癌、食管癌、胰腺癌、肺癌、卵巢癌、结肠癌、肝癌、头颈癌、胆囊癌及其转移瘤等癌症疾病。
• Therapy involving antibodies against Claudin 18.2 for treatment of cancer
  申请人：GANYMED PHARMACEUTICALS AG

  公开号：US10137195B2

  公开（公告）日：2018-11-27

  The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.

  本发明通常提供一种疗法，用于有效治疗和/或预防与表达CLDN18.2的细胞有关的疾病，特别是癌症疾病，如胃癌。本发明提供的数据表明，对患有胃食管癌的人类患者施用抗CLDN18.2抗体是安全和耐受性良好的，剂量至少为1000毫克/平方米。此外，报告还提供了数据，证明该抗体在这些患者体内具有充分的功能，可发挥抗肿瘤细胞的作用，并获得了抗肿瘤活性的证据。
• Combination therapy involving antibodies against claudin 18.2 for treatment of pancreatic cancer
  申请人：Ganymed Pharmaceuticals AG

  公开号：US10314890B2

  公开（公告）日：2019-06-11

  The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.

  本发明提供了一种联合疗法，用于有效治疗和/或预防与表达CLDN18.2的细胞有关的疾病，包括癌症疾病，如胰腺癌及其转移。
• Diagnosis and therapy of cancer involving cancer stem cells
  申请人：BioNTech AG

  公开号：US10604568B2

  公开（公告）日：2020-03-31

  The present invention provides methods for diagnosis or treatment of cancer diseases involving cancer stem cells comprising targeting CLDN6. In particular, the present invention provides a method of determining cancer stem cells comprising detecting cells expressing CLDN6, Furthermore, the present invention provides a method of treating or preventing cancer comprising inhibiting and/or eliminating cancer stem cells by administering an antibody having the ability of binding to CLDN6 to a cancer patient.

  本发明提供了诊断或治疗涉及癌症干细胞的癌症疾病的方法，包括靶向 CLDN6。特别是，本发明提供了一种确定癌症干细胞的方法，包括检测表达CLDN6的细胞。此外，本发明还提供了一种治疗或预防癌症的方法，包括通过向癌症患者施用具有与CLDN6结合能力的抗体来抑制和/或消除癌症干细胞。